Abeona Therapeutics (ABEO) Stock Forecast, Price Target & Predictions
ABEO Stock Forecast
Abeona Therapeutics stock forecast is as follows: an average price target of $6.00 (represents a -0.66% downside from ABEO’s last price of $6.04) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
ABEO Price Target
ABEO Analyst Ratings
Abeona Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 14, 2022 | - | Leerink Partners | $6.00 | $4.15 | 44.58% | -0.66% |
Abeona Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | - | - | - |
Avg Price Target | - | - | - |
Last Closing Price | $6.04 | $6.04 | $6.04 |
Upside/Downside | -100.00% | -100.00% | -100.00% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Jul 03, 2024 | H.C. Wainwright | - | Buy | Initialise |
May 16, 2024 | Cantor Fitzgerald | Overweight | Overweight | Hold |
Nov 14, 2022 | SVB Leerink | Market Perform | Market Perform | Hold |
Abeona Therapeutics Financial Forecast
Abeona Therapeutics Revenue Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 22 | Mar 22 | Dec 20 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Jun 15 | Mar 12 | Mar 11 | Jun 10 | Sep 09 | Jun 08 | Jun 02 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $68.00K | $346.00K | $3.00M | $7.00M | - | - | - | $2.60M | $186.00K | $235.00K | $282.00K | $1.85M | $150.00K | $105.00K | $144.00K | - | - |
Avg Forecast | $9.15M | $3.50M | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $166.67K | $1.00M | $253.73K | $5.37M | $1.40M | $120.00K | $300.00K | $778.50K | $559.44K | $219.23K | $183.53K | $232.65K | $2.58M | $160.71K | $172.86K | $87.03K | $118.53K | $216.67K |
High Forecast | $9.15M | $3.50M | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $166.83K | $1.00M | $304.48K | $5.37M | $1.40M | $120.00K | $300.00K | $778.50K | $671.33K | $263.07K | $220.23K | $279.18K | $3.09M | $192.86K | $207.43K | $104.43K | $142.24K | $260.00K |
Low Forecast | $9.15M | $3.50M | $125.00K | $125.00K | $100.00K | $100.00K | $100.00K | $166.50K | $1.00M | $202.99K | $5.37M | $1.40M | $120.00K | $300.00K | $778.50K | $447.55K | $175.38K | $146.82K | $186.12K | $2.06M | $128.57K | $138.28K | $69.62K | $94.82K | $173.33K |
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 3 | 17 | 10 | 16 | 8 | 10 | 16 | 18 | 20 | 19 | 10 | 14 | 10 | 15 | 10 | 11 | 8 |
Surprise % | - | - | - | - | - | - | - | - | 0.07% | 1.36% | 0.56% | 5.00% | - | - | - | 4.64% | 0.85% | 1.28% | 1.21% | 0.72% | 0.93% | 0.61% | 1.65% | - | - |
Abeona Therapeutics EBITDA Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 22 | Mar 22 | Dec 20 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Jun 15 | Mar 12 | Mar 11 | Jun 10 | Sep 09 | Jun 08 | Jun 02 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 3 | 17 | 10 | 16 | 8 | 10 | 16 | 18 | 20 | 19 | 10 | 14 | 10 | 15 | 10 | 11 | 8 |
EBITDA | - | - | - | - | - | - | - | - | $-10.37M | $-13.31M | $-13.34M | $-4.81M | $-15.34M | $-21.87M | $-16.90M | $-8.29M | $-5.00M | $-5.37M | $-3.98M | $-4.67M | $-1.67M | $1.99M | $-3.87M | - | - |
Avg Forecast | $-5.49M | $-2.10M | $-75.00K | $-75.00K | $-60.00K | $-60.00K | $-60.00K | $-100.00K | $-600.00K | $-9.52M | $-3.22M | $-840.00K | $-72.00K | $-180.00K | $-13.20M | $-8.72M | $-5.66M | $-3.72M | $-3.13M | $-11.41M | $-1.78M | $-103.71K | $-1.67M | $-1.83M | $-1.46M |
High Forecast | $-5.49M | $-2.10M | $-75.00K | $-75.00K | $-60.00K | $-60.00K | $-60.00K | $-99.90K | $-600.00K | $-7.62M | $-3.22M | $-840.00K | $-72.00K | $-180.00K | $-10.56M | $-6.98M | $-4.53M | $-2.97M | $-2.51M | $-9.12M | $-1.43M | $-82.97K | $-1.33M | $-1.46M | $-1.17M |
Low Forecast | $-5.49M | $-2.10M | $-75.00K | $-75.00K | $-60.00K | $-60.00K | $-60.00K | $-100.10K | $-600.00K | $-11.43M | $-3.22M | $-840.00K | $-72.00K | $-180.00K | $-15.84M | $-10.47M | $-6.79M | $-4.46M | $-3.76M | $-13.69M | $-2.14M | $-124.46K | $-2.00M | $-2.19M | $-1.75M |
Surprise % | - | - | - | - | - | - | - | - | 17.29% | 1.40% | 4.14% | 5.72% | 213.06% | 121.48% | 1.28% | 0.95% | 0.88% | 1.44% | 1.27% | 0.41% | 0.94% | -19.21% | 2.32% | - | - |
Abeona Therapeutics Net Income Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 22 | Mar 22 | Dec 20 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Jun 15 | Mar 12 | Mar 11 | Jun 10 | Sep 09 | Jun 08 | Jun 02 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 3 | 17 | 10 | 16 | 8 | 10 | 16 | 18 | 20 | 19 | 10 | 14 | 10 | 15 | 10 | 11 | 8 |
Net Income | - | - | - | - | - | - | - | - | $6.42M | $-20.99M | $-15.83M | $-7.24M | $-17.37M | $-23.92M | $-18.55M | $-8.46M | $-5.25M | $-5.54M | $-4.11M | $-4.89M | $-1.90M | $1.79M | $-4.07M | - | - |
Avg Forecast | $-8.20M | $-18.19M | $-21.77M | $-21.26M | $-20.11M | $-20.11M | $-17.52M | $-26.30M | $-38.42M | $-10.16M | $-128.07M | $-183.56M | $-558.01M | $-467.53M | $-14.50M | $-8.91M | $-5.95M | $-3.84M | $-3.24M | $-11.95M | $-2.03M | $2.44M | $-1.75M | $-1.99M | $-1.85M |
High Forecast | $-8.20M | $-18.19M | $-21.77M | $-21.26M | $-20.11M | $-19.05M | $-17.52M | $-26.30M | $-38.42M | $-8.13M | $-128.07M | $-183.56M | $-558.01M | $-467.53M | $-11.60M | $-7.13M | $-4.76M | $-3.07M | $-2.59M | $-9.56M | $-1.62M | $2.93M | $-1.40M | $-1.59M | $-1.48M |
Low Forecast | $-8.20M | $-18.19M | $-21.77M | $-21.26M | $-20.11M | $-21.16M | $-17.52M | $-26.30M | $-38.42M | $-12.20M | $-128.07M | $-183.56M | $-558.01M | $-467.53M | $-17.40M | $-10.69M | $-7.14M | $-4.61M | $-3.89M | $-14.34M | $-2.43M | $1.95M | $-2.10M | $-2.39M | $-2.22M |
Surprise % | - | - | - | - | - | - | - | - | -0.17% | 2.07% | 0.12% | 0.04% | 0.03% | 0.05% | 1.28% | 0.95% | 0.88% | 1.44% | 1.27% | 0.41% | 0.94% | 0.73% | 2.32% | - | - |
Abeona Therapeutics SG&A Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 22 | Mar 22 | Dec 20 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Jun 15 | Mar 12 | Mar 11 | Jun 10 | Sep 09 | Jun 08 | Jun 02 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 3 | 17 | 10 | 16 | 8 | 10 | 16 | 18 | 20 | 19 | 10 | 14 | 10 | 15 | 10 | 11 | 8 |
SG&A | - | - | - | - | - | - | - | - | $5.68M | $4.22M | $7.40M | $4.43M | $4.70M | $5.61M | $5.66M | $2.88M | $3.02M | $4.37M | $3.67M | $979.00K | $1.03M | $1.25M | $3.46M | - | - |
Avg Forecast | $51.52M | $19.71M | $703.86K | $703.86K | $563.09K | $563.09K | $563.09K | $938.48K | $5.63M | $1.43M | $30.22M | $7.88M | $675.71K | $1.69M | $4.38M | $3.15M | $1.23M | $1.03M | $1.31M | $2.39M | $904.96K | $973.34K | $490.04K | $667.43K | $1.22M |
High Forecast | $51.52M | $19.71M | $703.86K | $703.86K | $563.09K | $563.09K | $563.09K | $939.42K | $5.63M | $1.71M | $30.22M | $7.88M | $675.71K | $1.69M | $4.38M | $3.78M | $1.48M | $1.24M | $1.57M | $2.87M | $1.09M | $1.17M | $588.04K | $800.91K | $1.46M |
Low Forecast | $51.52M | $19.71M | $703.86K | $703.86K | $563.09K | $563.09K | $563.09K | $937.54K | $5.63M | $1.14M | $30.22M | $7.88M | $675.71K | $1.69M | $4.38M | $2.52M | $987.56K | $826.74K | $1.05M | $1.91M | $723.96K | $778.66K | $392.02K | $533.94K | $976.01K |
Surprise % | - | - | - | - | - | - | - | - | 1.01% | 2.96% | 0.24% | 0.56% | 6.96% | 3.32% | 1.29% | 0.91% | 2.45% | 4.22% | 2.80% | 0.41% | 1.13% | 1.29% | 7.06% | - | - |
Abeona Therapeutics EPS Forecast
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 22 | Mar 22 | Dec 20 | Sep 20 | Sep 19 | Jun 19 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | Jun 15 | Mar 12 | Mar 11 | Jun 10 | Sep 09 | Jun 08 | Jun 02 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | 3 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 3 | 17 | 10 | 16 | 8 | 10 | 16 | 18 | 20 | 19 | 10 | 14 | 10 | 15 | 10 | 11 | 8 |
EPS | - | - | - | - | - | - | - | - | $0.82 | $-3.62 | $-4.26 | $-1.93 | $-8.73 | $-12.22 | $-9.67 | $-4.50 | $-3.26 | $-4.23 | $-4.00 | $-253.26 | $-123.37 | $80.09 | $-416.95 | - | - |
Avg Forecast | $-0.16 | $-0.35 | $-0.42 | $-0.41 | $-0.39 | $-0.39 | $-0.34 | $-0.51 | $-0.75 | $-2.38 | $-2.50 | $-3.58 | $-10.89 | $-9.13 | $-7.95 | $-5.00 | $-4.25 | $-2.25 | $-1.77 | $213.75 | $-200.00 | $-187.50 | $-123.75 | $-487.50 | $-750.00 |
High Forecast | $-0.16 | $-0.35 | $-0.42 | $-0.41 | $-0.39 | $-0.37 | $-0.34 | $-0.51 | $-0.75 | $-2.38 | $-2.50 | $-3.58 | $-10.89 | $-9.13 | $-7.95 | $-4.00 | $-3.40 | $-1.80 | $-1.42 | $256.50 | $-160.00 | $-150.00 | $-99.00 | $-390.00 | $-600.00 |
Low Forecast | $-0.16 | $-0.35 | $-0.42 | $-0.41 | $-0.39 | $-0.41 | $-0.34 | $-0.51 | $-0.75 | $-2.38 | $-2.50 | $-3.58 | $-10.89 | $-9.13 | $-7.95 | $-6.00 | $-5.10 | $-2.70 | $-2.13 | $171.00 | $-240.00 | $-225.00 | $-148.50 | $-585.00 | $-900.00 |
Surprise % | - | - | - | - | - | - | - | - | -1.09% | 1.52% | 1.70% | 0.54% | 0.80% | 1.34% | 1.22% | 0.90% | 0.77% | 1.88% | 2.26% | -1.18% | 0.62% | -0.43% | 3.37% | - | - |
Abeona Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
CALA | Calithera Biosciences | $0.01 | $2.00 | 19900.00% | Hold |
ATHA | Athira Pharma | $0.64 | $18.00 | 2712.50% | Buy |
IVVD | Invivyd | $0.90 | $9.50 | 955.56% | Buy |
RVPH | Reviva Pharmaceuticals | $1.00 | $10.00 | 900.00% | Buy |
XFOR | X4 Pharmaceuticals | $0.53 | $3.67 | 592.45% | Buy |
CKPT | Checkpoint Therapeutics | $3.49 | $20.00 | 473.07% | Buy |
BDTX | Black Diamond Therapeutics | $2.99 | $14.75 | 393.31% | Buy |
CABA | Cabaletta Bio | $4.00 | $16.33 | 308.25% | Buy |
RGNX | REGENXBIO | $8.76 | $34.00 | 288.13% | Buy |
ADAP | Adaptimmune Therapeutics | $0.83 | $2.83 | 240.96% | Buy |
INZY | Inozyme Pharma | $4.42 | $14.67 | 231.90% | Buy |
ANEB | Anebulo Pharmaceuticals | $1.89 | $6.00 | 217.46% | Buy |
PDSB | PDS Bio | $3.23 | $9.00 | 178.64% | Buy |
DAWN | Day One Biopharmaceuticals | $14.81 | $38.80 | 161.99% | Buy |
AFMD | Affimed | $3.27 | $7.50 | 129.36% | Buy |
TERN | Terns Pharmaceuticals | $7.10 | $14.25 | 100.70% | Buy |
ACAD | ACADIA Pharmaceuticals | $14.62 | $26.57 | 81.74% | Buy |
MREO | Mereo BioPharma Group | $4.01 | $6.75 | 68.33% | Buy |
LPTX | Leap Therapeutics | $3.67 | $5.50 | 49.86% | Buy |
ABEO | Abeona Therapeutics | $6.04 | $6.00 | -0.66% | Buy |
ABEO Forecast FAQ
Is Abeona Therapeutics a good buy?
Yes, according to 3 Wall Street analysts, Abeona Therapeutics (ABEO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of ABEO's total ratings.
What is ABEO's price target?
Abeona Therapeutics (ABEO) average price target is $6 with a range of $6 to $6, implying a -0.66% from its last price of $6.04. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Abeona Therapeutics stock go up soon?
According to Wall Street analysts' prediction for ABEO stock, the company can go down by -0.66% (from the last price of $6.04 to the average price target of $6), down by -0.66% based on the highest stock price target, and down by -0.66% based on the lowest stock price target.
Can Abeona Therapeutics stock reach $9?
ABEO's average twelve months analyst stock price target of $6 does not support the claim that Abeona Therapeutics can reach $9 in the near future.
What are Abeona Therapeutics's analysts' financial forecasts?
Abeona Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $466.67K (high $466.83K, low $466.5K), average EBITDA is $-280K (high $-280K, low $-280K), average net income is $-84.029M (high $-82.97M, low $-85.087M), average SG&A $2.63M (high $2.63M, low $2.63M), and average EPS is $-1.64 (high $-1.62, low $-1.661). ABEO's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $12.9M (high $12.9M, low $12.9M), average EBITDA is $-7.74M (high $-7.74M, low $-7.74M), average net income is $-69.412M (high $-69.412M, low $-69.412M), average SG&A $72.64M (high $72.64M, low $72.64M), and average EPS is $-1.355 (high $-1.355, low $-1.355).
Did the ABEO's actual financial results beat the analysts' financial forecasts?
Based on Abeona Therapeutics's last annual report (Dec 2022), the company's revenue was $1.41M, beating the average analysts forecast of $1.25M by 12.78%. Apple's EBITDA was $-44.685M, beating the average prediction of $-10.122M by 341.46%. The company's net income was $-31.809M, missing the average estimation of $-48.585M by -34.53%. Apple's SG&A was $17.26M, beating the average forecast of $7.06M by 144.43%. Lastly, the company's EPS was $-4.05, beating the average prediction of $-3.125 by 29.60%. In terms of the last quarterly report (Dec 2022), Abeona Therapeutics's revenue was $68K, missing the average analysts' forecast of $1M by -93.20%. The company's EBITDA was $-10.372M, beating the average prediction of $-600K by 1628.67%. Abeona Therapeutics's net income was $6.42M, missing the average estimation of $-38.42M by -116.70%. The company's SG&A was $5.68M, beating the average forecast of $5.63M by 0.91%. Lastly, the company's EPS was $0.82, missing the average prediction of $-0.75 by -209.33%